$IRD

2019 Form 10-K Financial Statement

#000114036120003785 Filed on February 21, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.730M $2.240M $7.430M
YoY Change -22.88% 37.42% 11.9%
% of Gross Profit
Research & Development $5.477M $2.730M $13.11M
YoY Change -58.22% -16.26% 22.34%
% of Gross Profit
Depreciation & Amortization $3.000K $10.00K $50.00K
YoY Change -94.0% 0.0% 25.0%
% of Gross Profit
Operating Expenses $4.193M $4.966M $20.54M
YoY Change -79.58% 1.39% 18.34%
Operating Profit -$4.193M -$4.966M -$20.54M
YoY Change -79.58% 1.39% 18.34%
Interest Expense $1.409M $1.850M $5.800M
YoY Change -75.71% 41.22% -173.05%
% of Operating Profit
Other Income/Expense, Net -$68.00K $1.850M $6.169M
YoY Change -101.1% 41.67% -177.7%
Pretax Income -$6.169M -$3.120M -$14.37M
YoY Change -57.07% -13.09% -43.2%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.169M -$3.117M -$14.37M
YoY Change -57.07% -13.25% -43.2%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$8.727M -$4.105M -$20.83M
COMMON SHARES
Basic Shares Outstanding 37.52M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.22M $14.73M $14.73M
YoY Change -17.04% -45.1% -45.1%
Cash & Equivalents $9.220M $8.744M $8.740M
Short-Term Investments $3.000M $5.980M $5.980M
Other Short-Term Assets $450.0K $555.4K $1.180M
YoY Change -61.86% 8.78% -9.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.66M $15.90M $15.90M
YoY Change -20.38% -43.49% -43.5%
LONG-TERM ASSETS
Property, Plant & Equipment $280.0K $112.5K $110.0K
YoY Change 154.55% -7.4% -8.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $30.00K $30.00K $30.00K
YoY Change 0.0% 0.0% 0.0%
Other Assets
YoY Change
Total Long-Term Assets $310.0K $143.3K $140.0K
YoY Change 121.43% -5.9% -6.67%
TOTAL ASSETS
Total Short-Term Assets $12.66M $15.90M $15.90M
Total Long-Term Assets $310.0K $143.3K $140.0K
Total Assets $12.97M $16.04M $16.04M
YoY Change -19.14% -43.29% -43.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $490.0K $550.0K $550.0K
YoY Change -10.91% -38.89% -38.89%
Accrued Expenses $920.0K $2.610M $2.610M
YoY Change -64.75% 11.54% 11.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.910M $3.153M $3.150M
YoY Change -7.62% -2.4% -2.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $110.0K $2.330M $2.330M
YoY Change -95.28% -71.89% -71.89%
Total Long-Term Liabilities $110.0K $2.330M $2.330M
YoY Change -95.28% -71.89% -71.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.910M $3.153M $3.150M
Total Long-Term Liabilities $110.0K $2.330M $2.330M
Total Liabilities $3.010M $5.480M $5.480M
YoY Change -45.07% -52.43% -52.43%
SHAREHOLDERS EQUITY
Retained Earnings -$154.7M
YoY Change 10.24%
Common Stock $165.3M
YoY Change 5.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.960M -$1.699M $10.56M
YoY Change
Total Liabilities & Shareholders Equity $12.97M $16.04M $16.04M
YoY Change -19.14% -43.29% -43.3%

Cashflow Statement

Concept 2019 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$6.169M -$3.117M -$14.37M
YoY Change -57.07% -13.25% -43.2%
Depreciation, Depletion And Amortization $3.000K $10.00K $50.00K
YoY Change -94.0% 0.0% 25.0%
Cash From Operating Activities -$3.593M -$4.620M -$18.84M
YoY Change -80.93% 24.86% 22.17%
INVESTING ACTIVITIES
Capital Expenditures $25.00K $0.00 -$40.00K
YoY Change -162.5% -100.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities $3.120M $2.000M $11.95M
YoY Change -73.89% -166.45% -228.49%
Cash From Investing Activities -$25.00K $2.000M $11.91M
YoY Change -100.21% -165.36% -227.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.654M $6.873M
YoY Change 11.36% -58.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.704M 6.770M 6.773M
YoY Change -30.55% -9.01% -69.37%
NET CHANGE
Cash From Operating Activities -3.593M -4.620M -18.84M
Cash From Investing Activities -25.00K 2.000M 11.91M
Cash From Financing Activities 4.704M 6.770M 6.773M
Net Change In Cash 1.086M 4.150M -154.9K
YoY Change -801.31% 510.29% -94.22%
FREE CASH FLOW
Cash From Operating Activities -$3.593M -$4.620M -$18.84M
Capital Expenditures $25.00K $0.00 -$40.00K
Free Cash Flow -$3.618M -$4.620M -$18.80M
YoY Change -80.75% 26.92% 22.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001228627
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4019141
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q2 dei Entity Public Float
EntityPublicFloat
20690919
CY2019 dei Entity Registrant Name
EntityRegistrantName
REXAHN PHARMACEUTICALS, INC.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 rexn Amortization Of Deferred Research And Development Contribution
AmortizationOfDeferredResearchAndDevelopmentContribution
-375000
CY2018Q4 rexn Cash Paid In Exchange For Legal Services
CashPaidInExchangeForLegalServices
627211
CY2018Q4 rexn Deferred Tax Assets Book Tax Differences On Assets And Liabilities
DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities
195000
CY2019Q4 rexn Deferred Tax Assets Book Tax Differences On Assets And Liabilities
DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities
464000
CY2019 rexn Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00
CY2019 rexn Defined Contribution Plan Employer Matching Contribution
DefinedContributionPlanEmployerMatchingContribution
1
CY2019 rexn Defined Contribution Plan Maximum Annual Contribution Per Employee Additional Percent On Deferral
DefinedContributionPlanMaximumAnnualContributionPerEmployeeAdditionalPercentOnDeferral
0.5
CY2009Q2 rexn First Achievement Of Marketing Approvals
FirstAchievementOfMarketingApprovals
P30D
CY2019 rexn Fixed Contingent Consideration
FixedContingentConsideration
3000000
CY2019 rexn Investment Warrants Exercised Number
InvestmentWarrantsExercisedNumber
CY2019 rexn Investment Warrants Exercised Weighted Average Exercise Price
InvestmentWarrantsExercisedWeightedAverageExercisePrice
CY2019 rexn Investment Warrants Expired Number
InvestmentWarrantsExpiredNumber
39683
CY2019 rexn Investment Warrants Expired Weighted Average Exercise Price
InvestmentWarrantsExpiredWeightedAverageExercisePrice
153.60
CY2018Q4 rexn Investment Warrants Fair Value
InvestmentWarrantsFairValue
2307586
CY2019Q4 rexn Investment Warrants Fair Value
InvestmentWarrantsFairValue
41717
CY2018 rexn Investment Warrants Fair Value Assumptions Estimated Additional Shares Issued Upon Dilutive Event
InvestmentWarrantsFairValueAssumptionsEstimatedAdditionalSharesIssuedUponDilutiveEvent
0.05
CY2019 rexn Investment Warrants Fair Value Assumptions Estimated Additional Shares Issued Upon Dilutive Event
InvestmentWarrantsFairValueAssumptionsEstimatedAdditionalSharesIssuedUponDilutiveEvent
0.50
CY2018 rexn Investment Warrants Fair Value Assumptions Estimated Dividend
InvestmentWarrantsFairValueAssumptionsEstimatedDividend
CY2019 rexn Investment Warrants Fair Value Assumptions Estimated Dividend
InvestmentWarrantsFairValueAssumptionsEstimatedDividend
CY2018 rexn Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate
InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate
1.05
CY2019 rexn Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate
InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate
1.02
CY2018 rexn Investment Warrants Fair Value Assumptions Trading Market Prices
InvestmentWarrantsFairValueAssumptionsTradingMarketPrices
11.16
CY2019 rexn Investment Warrants Fair Value Assumptions Trading Market Prices
InvestmentWarrantsFairValueAssumptionsTradingMarketPrices
1.91
CY2018Q4 rexn Investment Warrants Issued Number
InvestmentWarrantsIssuedNumber
480771
CY2019 rexn Investment Warrants Issued Number
InvestmentWarrantsIssuedNumber
895886
CY2019Q1 rexn Investment Warrants Issued Number
InvestmentWarrantsIssuedNumber
895886
CY2019 rexn Investment Warrants Issued Weighted Average Exercise Price
InvestmentWarrantsIssuedWeightedAverageExercisePrice
9.60
CY2019 rexn Investment Warrants Weighted Average Remaining Contractual Term
InvestmentWarrantsWeightedAverageRemainingContractualTerm
P3Y8M12D
CY2018Q4 rexn Placement Agent Warrants Fair Value At Issuance
PlacementAgentWarrantsFairValueAtIssuance
286906
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-14368530
CY2019Q4 rexn Research And Development Estimated Cost To Complete Contracts With Vendors
ResearchAndDevelopmentEstimatedCostToCompleteContractsWithVendors
1750000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1265731
CY2019Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
488285
CY2019Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
471700
CY2019Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
84576
CY2019Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
221170
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5738227
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
254344
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
313700
CY2018 us-gaap Operating Expenses
OperatingExpenses
20537673
CY2019 us-gaap Operating Expenses
OperatingExpenses
11215003
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-20537673
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-11215003
CY2018 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
368750
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5476776
CY2018 us-gaap Revenues
Revenues
CY2019 us-gaap Revenues
Revenues
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2738506
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3960163
CY2018Q4 us-gaap Assets
Assets
16042926
CY2019Q4 us-gaap Assets
Assets
12968772
CY2018Q4 us-gaap Assets Current
AssetsCurrent
15899668
CY2019Q4 us-gaap Assets Current
AssetsCurrent
12663973
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2997220
CY2018Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
547519
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-39251
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
108214
CY2018Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
140637
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
709117
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
271723
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
2997220
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2084
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
2995136
CY2018Q4 rexn Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
7500000
CY2019Q1 rexn Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
8600000
CY2018Q4 rexn Public Offering Closing Costs
PublicOfferingClosingCosts
896117
CY2019Q1 rexn Public Offering Closing Costs
PublicOfferingClosingCosts
1046172
CY2009Q2 rexn Research And Developement Agreement One Time Milestone Payment
ResearchAndDevelopementAgreementOneTimeMilestonePayment
1000000
CY2018Q1 rexn Research And Development Arrangement Licensing Revenue
ResearchAndDevelopmentArrangementLicensingRevenue
5000000
CY2018Q1 rexn Research And Development Arrangement Licensing Revenue Percentage
ResearchAndDevelopmentArrangementLicensingRevenuePercentage
0.50
CY2018Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
5981520
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
2997220
CY2019 rexn Warrant Fundamental Transaction Timing Date
WarrantFundamentalTransactionTimingDate
2020-04
CY2018 rexn Warrant Fundamental Transaction Timing Description
WarrantFundamentalTransactionTimingDescription
End of warrant term
CY2018Q4 rexn Warrant Liabilities
WarrantLiabilities
2307586
CY2019Q4 rexn Warrant Liabilities
WarrantLiabilities
41717
CY2018Q4 rexn Warrants Exercise Price
WarrantsExercisePrice
37.52
CY2019Q4 rexn Warrants Exercise Price
WarrantsExercisePrice
22.10
CY2018 rexn Warrants Issued
WarrantsIssued
4841830
CY2019 rexn Warrants Issued
WarrantsIssued
4735913
CY2018Q4 rexn Warrants Issued Per Share Of Stock Issued In Unit Offering
WarrantsIssuedPerShareOfStockIssuedInUnitOffering
1
CY2019Q1 rexn Warrants Issued Per Share Of Stock Issued In Unit Offering
WarrantsIssuedPerShareOfStockIssuedInUnitOffering
1
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3152550
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1265731
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
3152550
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17836
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2084
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
165267656
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
173278144
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1228335
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
456750
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1228335
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
456750
CY2019Q4 us-gaap Billed Contract Receivables
BilledContractReceivables
1500000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
12200000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8899154
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8744301
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9219547
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-154853
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
475246
CY2019Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
8969547
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
20.04
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.60
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1065286
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1921489
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3122843
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4019141
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3122843
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4019141
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
312
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
402
CY2018Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16042926
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12968772
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3152550
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2905496
CY2018Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2307586
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
41717
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:10.8pt 0pt 0pt;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Concentration of Credit Risk</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">ASC 825, &#x201C;Financial Instruments,&#x201D; requires disclosure of any significant off balance sheet risk and credit risk concentration.&nbsp;&nbsp;The Company does not have significant off</font><font style="display: inline;">&#8209;balance sheet risk or credit concentration</font><font style="display: inline;">.&nbsp;&nbsp;The Company maintains cash and cash equivalents with major financial institutions.&nbsp;&nbsp;From time to time the Company has funds on deposit with commercial banks that exceed federally insured limits.&nbsp;&nbsp;The balances are insured by the Federal Deposit Insurance Corporation up to $250,000. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">At December 31, 201</font><font style="display: inline;">9</font><font style="display: inline;">, the Company&#x2019;s uninsured cash balance was </font><font style="display: inline;">$8,969,547</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;"> Management does not consider this to be a significant credit risk as the banks are large, established financial institutions.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1500000
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
19900
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41184000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43844000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1608000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1191000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42987000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45499000
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
120558
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
71568
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.02
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
48211
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
40992
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.25
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.18
CY2018Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
682263
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5546049
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2265869
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
155280
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17274
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9594
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7428615
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1886819
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1500000
CY2018 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
36824
CY2019 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-3724
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-608143
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
22650
CY2019 us-gaap Lease Cost
LeaseCost
229701
CY2019Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.11
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
220644
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
65364
CY2018Q4 us-gaap Liabilities
Liabilities
5480036
CY2019Q4 us-gaap Liabilities
Liabilities
3010818
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;text-indent:-21.6pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-weight:bold;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">1.</font><font style="display: inline;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">Operations and Organization</font> </p> <p style="margin:10.8pt 0pt 0pt 23.75pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">Rexahn Pharmaceuticals, Inc. (the &#x201C;Company&#x201D;), a Delaware corporation, is a biopharmaceutical company whose principal operations are the development of innovative treatments for cancer.&nbsp;&nbsp;The Company had an accumulated deficit of </font><font style="display: inline;">$</font><font style="display: inline;color:#000000;">163,322,676</font><font style="display: inline;"> at December 31, 2019 and anticipates incurring losses in the foreseeable future.&nbsp;&nbsp;In September 2019, the Company commenced a process to explore and evaluate strategic alternatives to enhance shareholder value and engaged a financial advisory firm to assist in the process.</font><font style="display: inline;"> &nbsp; &nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">&#xFEFF;</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The Company believes that its cash, cash equivalents and marketable securities of approximately </font><font style="display: inline;">$12.2</font><font style="display: inline;"> million as of December 31, 2019 will be sufficient to cover its cash flow requirements for its current activities for at least the next 12 months from the date these financial statements were issued.&nbsp; </font> </p> <p style="margin:10.8pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-weight:bold;background-color:yellow;">&#xFEFF;</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6772789
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7653828
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11910996
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3098551
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18838638
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10277133
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-8635434
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6169143
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
200948
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
203370
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
139765
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
63605
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
197224
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
203348
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
147086000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
156586000
CY2019 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2021-12-31
CY2018Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1782131
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
555430
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
447206
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
39050
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
19920
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
39050
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
19920
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
618417
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
CY2018 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
39224
CY2019 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
19383
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8887566
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1173847
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
447206
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Reclassification</font> </p> <p style="margin:10.8pt 0pt 0pt 22.5pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">Certain amounts in the prior year&#x2019;s financial statements have been reclassified to conform to the current year presentation with no material impact on the financial statements.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6872789
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7653828
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11950220
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12000000
CY2019 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
5500
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
821590
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
347493
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112473
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75770
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13109058
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154687242
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163322676
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3000000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
380935
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
30785
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
25681
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1228335
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
456750
CY2018Q4 us-gaap Share Price
SharePrice
15.60
CY2019Q1 us-gaap Share Price
SharePrice
9.60
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
16768596
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10562890
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
9957954
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083
CY2018Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
480770
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
895834
CY2018 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
22650
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6872789
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7553828
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:10.8pt 0pt 0pt 23.75pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Use of Estimates</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">&#xFEFF;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America </font><font style="display: inline;">(&#x201C;U.S. GAAP&#x201D;) </font><font style="display: inline;">requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future.&nbsp;&nbsp;Actual results may ultimately differ from these estimates.&nbsp;&nbsp;These estimates are reviewed periodically and as adjustments become necessary, they are reported in earnings in the period in which they become available.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
28753

Files In Submission

Name View Source Status
0001140361-20-003785-index-headers.html Edgar Link pending
0001140361-20-003785-index.html Edgar Link pending
0001140361-20-003785.txt Edgar Link pending
0001140361-20-003785-xbrl.zip Edgar Link pending
ex23_1.htm Edgar Link pending
ex24_1.htm Edgar Link pending
ex31_1.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex4_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rexn-20191231.xml Edgar Link completed
rexn-20191231.xsd Edgar Link pending
rexn-20191231_cal.xml Edgar Link unprocessable
rexn-20191231_def.xml Edgar Link unprocessable
rexn-20191231_lab.xml Edgar Link unprocessable
rexn-20191231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending